CA-AKTANA
4.5.2022 13:57:13 CEST | Business Wire | Press release
Aktana , the leader in intelligent customer engagement for the global life sciences industry, announced that Almirall, LLC selected its Contextual Intelligence Engine for nationwide rollout across two leading brands in the United States. The global skin health leader deployed Aktana’s solution in early January and is already outpacing expectations with 86% rep engagement and a sharp increase in rep productivity. Aktana’s Contextual Intelligence 360 is a modular solution that enables commercial and medical teams to rapidly scale AI-driven programs that personalize the customer experience, coordinate engagement, and optimize the entire HCP journey across channels.
With more than 300 deployments across 50+ use cases, Aktana has been refining its commercial life sciences intelligence platform for more than a decade. More than half of the world's top-20 pharmaceutical companies rely on Aktana to coordinate and optimize personalized omnichannel engagement with HCPs. With their recent deployment, Almirall now joins this group of industry innovators using Aktana’s modular AI solution to transform their commercial approach.
“We aim to be the global leader in medical dermatology and intend to act like a leader by replacing clunky processes with agile, best-in-class technologies,” said Vincent Cerio, head of commercial operations at Almirall. “We have seen swift and remarkable results. Our teams have embraced Aktana’s Contextual Intelligence 360 solution, seeing the impact on customer engagement and individual productivity. The rep locator module, for instance – which predicts how far HCPs will be from a rep’s expected location – has helped reps optimize their days, minimizing ‘windshield’ time.”
Change management is another critical aspect of AI adoption. Aktana incorporates change management functionality into its engine, such as seamless workflow integration and transparent suggestion logic, to build user confidence and accelerate onboarding. “At Aktana’s suggestion, we also invested in a formal change management program grounded in ongoing, honest communication. A team of early adopters provided feedback and served as internal champions, inspiring others to use Aktana’s system and experience the same benefits they were experiencing,” explained Cerio. “User acceptance has been great, so we want to expand our use of the system in various ways – from content optimization to next-best-action suggestions for our medical science liaisons.”
Contextual Intelligence 360 is powered by Aktana’s next-generation Contextual Intelligence Engine , which applies machine learning, explainable AI (xAI), human intelligence, and other advanced technologies to mine data and insights from all sources – from prescribing habits and patient demographics to past brand interactions and field rep insights. Dynamic, real-time recommendations ensure field and marketing teams work together to create meaningful HCP partnerships that continuously evolve.
“As a fast-growing medical dermatology company, Almirall recognizes the urgency and importance of leveraging advanced AI technology to empower its commercial teams,” said Derek Choy, president of Aktana. “With its flexible architecture, Aktana’s Contextual Intelligence 360 made it possible for Almirall to implement quickly while laying the foundation to scale into other areas and geographies when they’re ready to expand.”
About Aktana
Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more information, visit www.aktana.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005413/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Strengthens UK Manufacturing Network as Whitman Facility Celebrates 60 Years of British Craftsmanship8.6.2026 17:14:00 CEST | Press release
As The Estée Lauder Companies’ (NYSE: EL) Whitman manufacturing facility celebrates its 60th anniversary, the company today announced a strategic investment that will strengthen its UK manufacturing network, further reinforcing its long-standing commitment to British craftsmanship, innovation, and growth in prestige fragrance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608415843/en/ From left to right: Jo Dancey, Global Brand President, Jo Malone London; Alex Gregorian, SVP, Global Manufacturing & Engineering; Roberto Canevari, Chief Value Chain Officer; Nadine Graf, President, EUKEM; Stéphane de La Faverie, President and Chief Executive Officer; William P. Lauder, Chair of the Board of Directors; Maria Genouzos, VP, EUKEM and APAC Manufacturing; Pernilla Nyberg, SVP, General Manager, UK & Ireland; Jamal Chamariq, SVP, EUKEM & TR Value Chain; and Ben Smith, Whitman Plant Manager, celebrate the 60th anniversary of The
IQM and Real Asset Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination8.6.2026 16:16:00 CEST | Press release
RAAQ Extraordinary General Meeting Scheduled for June 25, 2026 IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced today that the registration statement on Form F-4 (the “Registration Statement”), relating to their previously announced business combination, has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) on June 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608520188/en/ IQM Radiance quantum computer The extraordinary general meeting of RAAQ’s shareholders in connection with the proposed business combination (the “Extraordinary General Meeting”) will be held on June 25, 2026. The proxy statement/prospectus relating to the Extraordinary General Meeting was mailed to RAAQ’s shareholders of record
Monster Hunter Wilds: Ascendance to Launch in 2027!8.6.2026 15:00:00 CEST | Press release
– Monster Hunter: World, released in 2018, surpassed 30 million units as Capcom looks to expand its global user base – Capcom Co., Ltd. (TOKYO:9697) today announced that Monster Hunter Wilds: Ascendance, a massive expansion for Monster Hunter Wilds, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608183725/en/ Monster Hunter Wilds Ascendance key art Monster Hunter Wilds: Ascendance is a massive expansion (paid content) for Monster Hunter Wilds, which was released in February 2025. As a continuation of the main game’s story, the expansion will further deepen the gameplay experience with new content including new quest ranks, locales, additional monsters and expanded weapon actions through new gameplay features. The company is currently developing the title for release in 2027. Capcom is also developing Monster Hunter Wilds for Nintendo Switch™ 2 in addition to the existing platforms. Furthe
Resident Evil Veronica to Launch in 2027!8.6.2026 15:00:00 CEST | Press release
– Capcom aims to further enhance the IP’s value by remaking a popular title of the series – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Veronica, the latest title in the Resident Evil series, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608994346/en/ Resident Evil Veronica key art The Resident Evil franchise features survival horror games in which players utilize a variety of weapons and other items to survive terrifying situations. Supported by a passionate global fanbase, cumulative game sales since the first title in this flagship series debuted in 1996 exceed 201 million* units. Resident Evil Veronica is a remake of the original Resident Evil Code: Veronica, released in the year 2000. While preserving the appeal of the original, Capcom is developing the 2027 release as the latest installment of the Resident Evil series, with a reimagined story and high-quality g
Neuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company’s Advancement Toward Commercialization8.6.2026 15:00:00 CEST | Press release
Ulf Wiinberg appointed to Board of DirectorsWilliam “Bill” MacKenzie hired as Senior Vice President – Finance Neuraptive Therapeutics today announced the appointment of Ulf Wiinberg to its Board of Directors and William “Bill” MacKenzie as Senior Vice President – Finance. Mr. Wiinberg is a seasoned biotechnology, pharmaceutical and healthcare industries executive with an extensive global career. As a member of the Board of Directors, he will contribute strategic guidance and industry expertise to support the Company’s development and commercialization strategy. Mr. Wiinberg’s experience includes serving as CEO of X-Vax Technology, Inc. from 2017 until 2024 and prior to that, he was CEO of Lundbeck from 2008 until 2014. From 2002 to 2008, he was a member of Wyeth’s Management Committee and during this time, he was Worldwide President of Wyeth Consumer Healthcare from 2002 to 2005, and President of Europe/Middle East/Africa until 2008, when Wyeth was acquired by Pfizer. Ulf serves as a d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
